The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Masoud Bitaraf
No Relationships to Disclose
 
Mohammad Alyamani
No Relationships to Disclose
 
Jinyuan Shi
No Relationships to Disclose
 
Nikou Fotouhi
No Relationships to Disclose
 
Lauren Howard
Consulting or Advisory Role - Tempus
 
Jennifer Freedman
Stock and Other Ownership Interests - TheraSplice
Research Funding - Janssen Scientific Affairs (Inst)
Patents, Royalties, Other Intellectual Property - Inventor, 15/344,222, "Biomarkers for the Identification of Prostate Cancer and Methods of Use", filed November 4, 2016, pending.; Inventor, PCT/US19/23670, “Splice-Switching Oligonucleotides and Methods of Use”, filed March 22, 2019, notice of allowance June 7, 2021.
 
Daniel George
Leadership - Capio BioSciences
Stock and Other Ownership Interests - BMS; Pfizer
Honoraria - Astellas Pharma; AstraZeneca; Axess Oncology; Bayer; Candel Therapeutics; Eisai; IDEOlogy Health; Janssen Oncology; Merck; Millennium Medical Publishing; Novartis; OncLive; Pfizer; Sumitomo; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Candel Theraputics; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Novartis; Pfizer; Physicans' Education Resource
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Convergent Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Novartis; Pfizer
 
Nima Sharifi
Consulting or Advisory Role - Astellas Pharma
Patents, Royalties, Other Intellectual Property - A patent application has been filed by Cleveland Clinic for a method of steroid-dependent disease treatment based on HSD3B1. Nima Sharifi is a co-inventor on this patent application